Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. Methods: Eculizumab (1,200 mg every 2 weeks for 22.7 months [median]) was administered to 117 patients. Results: The safety profile of eculizumab was consistent with REGAIN; no cases of meningococcal infection were reported during the interim analysis period. Myasthenia gravis exacerbation rate was reduced by 75% from the year before REGAIN (P < 0.0001). Improvements with eculizumab in activities of daily living, muscle strength, functional ability, and quality of life in REGAIN were maintained through 3 years; 56% of patients achieved minimal manifestations or pharmacological remission. Patients who had received placebo during REGAIN experienced rapid and sustained improvements during open-label eculizumab (P < 0.0001). Discussion: These findings provide evidence for the long-term safety and sustained efficacy of eculizumab for refractory gMG. Muscle Nerve 2019.

Long-term safety and efficacy of eculizumab in generalized myasthenia gravis / Muppidi S., Utsugisawa K., Benatar M., Murai H., Barohn R.J., Illa I., Jacob S., Vissing J., Burns T.M., Kissel J.T., Nowak R.J., Andersen H., Casasnovas C., de Bleecker J.L., Vu T.H., Mantegazza R., O'Brien F.L., Wang J.J., Fujita K.P., Howard J.F., et al.. - In: MUSCLE & NERVE. - ISSN 0148-639X. - ELETTRONICO. - 60:(2019), pp. 14-24. [10.1002/mus.26447]

Long-term safety and efficacy of eculizumab in generalized myasthenia gravis

D'Amato V.
Membro del Collaboration Group
;
2019

Abstract

Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. Methods: Eculizumab (1,200 mg every 2 weeks for 22.7 months [median]) was administered to 117 patients. Results: The safety profile of eculizumab was consistent with REGAIN; no cases of meningococcal infection were reported during the interim analysis period. Myasthenia gravis exacerbation rate was reduced by 75% from the year before REGAIN (P < 0.0001). Improvements with eculizumab in activities of daily living, muscle strength, functional ability, and quality of life in REGAIN were maintained through 3 years; 56% of patients achieved minimal manifestations or pharmacological remission. Patients who had received placebo during REGAIN experienced rapid and sustained improvements during open-label eculizumab (P < 0.0001). Discussion: These findings provide evidence for the long-term safety and sustained efficacy of eculizumab for refractory gMG. Muscle Nerve 2019.
2019
60
14
24
Muppidi S.; Utsugisawa K.; Benatar M.; Murai H.; Barohn R.J.; Illa I.; Jacob S.; Vissing J.; Burns T.M.; Kissel J.T.; Nowak R.J.; Andersen H.; Casasno...espandi
File in questo prodotto:
File Dimensione Formato  
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 274.38 kB
Formato Adobe PDF
274.38 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1258325
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 233
  • ???jsp.display-item.citation.isi??? 188
social impact